# TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

> **NCT05563480** · PHASE2 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
- **DRUG:** TQB2618 injection; Penpulimab injection

## Key facts

- **NCT ID:** NCT05563480
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-27
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-05-28
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05563480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05563480, "TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05563480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*